Tonix Pharm Holdings (TNXP) Stock Price, Quote & News

Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat and prevent human disease. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as immunology, infectious disease, and rare disease product candidates. The company's products pipeline include TNX-102 SL (cyclobenzaprine HCl sublingual tablet), for...

Industry: Biotechnology

Sector: Healthcare

Phone: 862 799 8599

Fax: 862 904 8163

Website: www.tonixpharma.com

Address:

26 Main Street, Suite 101, Chatham, United States

AlwaysABullNeverABear Jul. 16 at 5:59 PM

$TNXP

0 · Reply

asweidan Jul. 16 at 5:46 PM

$TNXP The amount of selling at $44.50+ is massive. This is going to run out and then boom. However, it is massive. Many 500 shares being sold at a time.

0 · Reply

iceh9 Jul. 16 at 5:34 PM

$RGTI $TNXP

0 · Reply

BiotechBonesaw Jul. 16 at 5:20 PM

$TNXP are you a good family member, friend, and neighbor? Here is the test: How many loved ones or just friendly acquaintances have you told about Tonix’s potential in fibromyalgia & long COVID alone? This dip is another buying opportunity and I’m tired of using my thumbs to preach about being a Tonmya Pioneer. Buying this now that my fresh powder has been unloaded. And am prepared to buy more if it drops further (or another biotech I own gets bought 🤷‍♂️). Here we gooooo 🚀

0 · Reply

Supplement Jul. 16 at 5:02 PM

$TNXP More good news! Tonix Pharma Plans Sales Force for TNX-102 SL 💼 Why Building a Sales Force Is Lucrative Signals Confidence in Approval You don’t hire 70–90 sales reps on speculation. Tonix clearly believes FDA approval is very likely — otherwise, they wouldn’t invest in infrastructure prematurely. This reduces perceived regulatory risk for investors.

2 · Reply

YEHONATAN101 Jul. 16 at 4:57 PM

$TNXP IN

0 · Reply

halokidokies Jul. 16 at 4:55 PM

$TNXP merger at rsls. Could pop more than XAGE did

0 · Reply

Joe676 Jul. 16 at 4:53 PM

$TNXP Added a few more

0 · Reply

754654DailyQualityStocks Jul. 16 at 4:50 PM

$TNXP $CRWV $BABA $BA @SRQQT

0 · Reply

Oran1 Jul. 16 at 4:49 PM

$TNXP month before approval and u sell it ? Idk what is going on

0 · Reply

Tonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate TNX-801 at the Vaccine Congress 2025

Jul 9, 2025, 4:01 PM EDT - 6 days ago

Tonix Pharmaceuticals Announces On-line Publication of Phase 3 RESILIENT Trial Results of TNX-102 SL for Fibromyalgia in the Peer Reviewed Journal, Pain Medicine

Jul 7, 2025, 7:00 AM EDT - 9 days ago

Tonix Pharmaceuticals Announces Oral Presentation on Mpox and Smallpox vaccine candidate TNX-801 at the Vaccine Congress 2025

Jul 2, 2025, 7:00 AM EDT - 14 days ago

Tonix Pharmaceuticals Announces Peer-Reviewed Publication in Cancer Cell Journal Highlighting Positive Preclinical Data of mTNX-1700 in Gastric Cancer Animal Models

Jun 30, 2025, 7:00 AM EDT - 16 days ago

Tonix Pharmaceuticals Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

Jun 16, 2025, 11:30 AM EDT - 4 weeks ago

Tonix Pharmaceuticals: Big Risk, Bigger Reward - Initiating With A Buy

Jun 16, 2025, 7:00 AM EDT - 4 weeks ago

Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the Annual European Congress of Rheumatology (EULAR) 2025

Jun 13, 2025, 7:30 AM EDT - 4 weeks ago

Tonix Pharmaceuticals: Is The Recent Sell-Off A Buy Occasion?

Jun 13, 2025, 7:00 AM EDT - 4 weeks ago

Tonix Pharmaceuticals Announces Appointment of Commercial Industry Veteran, James “Jim” Hunter, to Board of Directors

Jun 10, 2025, 7:00 AM EDT - 5 weeks ago

Tonix Pharmaceuticals Announces Presentation at the 2025 BIO International Convention

Jun 5, 2025, 7:00 AM EDT - 5 weeks ago

Tonix Pharmaceuticals Announces Poster Presentation at the Annual European Congress of Rheumatology (EULAR) 2025

May 22, 2025, 7:00 AM EDT - 7 weeks ago

Tonix Pharmaceuticals Announces Presentation at the A.G.P. Annual Healthcare Company Showcase

May 21, 2025, 7:00 AM EDT - 2 months ago

Tonix Pharmaceuticals Announces First Patient Dosed in Phase 2 OASIS Study of TNX-102 SL for Reduction of Acute Stress Reaction

May 14, 2025, 7:00 AM EDT - 2 months ago

Tonix Pharmaceuticals Announces Appointment of Joseph Hand, Esq., as General Counsel and Executive Vice President of Operations

May 12, 2025, 4:30 PM EDT - 2 months ago

Tonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Highlights

Apr 29, 2025, 9:05 AM EDT - 2 months ago

Tonix Pharmaceuticals Presented Preclinical Data on Gastric Cancer Models at the American Association for Cancer Research (AACR) 2025 Annual Meeting

Apr 24, 2025, 7:55 AM EDT - 2 months ago

Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress Washington 2025

Apr 16, 2025, 7:00 AM EDT - 3 months ago

Tonix Pharmaceuticals Announces Oral Presentation and Panel Participation at the World Vaccine Congress Washington 2025

Apr 9, 2025, 7:00 AM EDT - 3 months ago

Tonix Pharmaceuticals and Makana Therapeutics Announce Collaboration Combining Tonix's Anti-CD40L Monoclonal Antibody (TNX-1500) with Makana's Genetically Engineered Organs in Preclinical and Clinical Xenotransplantation Studies

Apr 7, 2025, 7:00 AM EDT - 3 months ago

Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting

Apr 2, 2025, 7:00 AM EDT - 3 months ago

Tonix Pharmaceuticals to Present at the 2025 Jones Trading Healthcare and Innovation Conference

Apr 1, 2025, 7:00 AM EDT - 3 months ago

Tonix Pharmaceuticals Launches TONIX ONE™, a Fully-Integrated Digital Platform Designed to Help Patients Better Understand and Manage Their Migraine Condition

Mar 31, 2025, 7:00 AM EDT - 3 months ago

Tonix's Experimental Non-Opioid Analgesic Treatment for Fibromyalgia Could Start Bringing Relief Later This Year

Mar 27, 2025, 7:00 AM EDT - 3 months ago

Tonix Pharmaceuticals Announces Presentation at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting

Mar 26, 2025, 2:30 AM EDT - 4 months ago

Tonix Pharmaceuticals: Potential To Have 'First' New Fibromyalgia Drug In 15 Years

Mar 25, 2025, 8:16 AM EDT - 4 months ago

Top 2 Health Care Stocks That Are Ticking Portfolio Bombs

ARQT

Mar 24, 2025, 8:00 AM EDT - 4 months ago

Tonix Pharmaceuticals Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for TNX-102 SL for the Management of Fibromyalgia

Mar 20, 2025, 7:00 AM EDT - 4 months ago

As Mpox Cases Spread Around the World, Tonix Pharmaceuticals' Single-Dose Vaccine TNX-801 Has Potential to Slow the Spread

Mar 19, 2025, 8:15 AM EDT - 4 months ago

Absci Posts Downbeat Results, Joins HealthEquity, Tonix Pharmaceuticals And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

ABSI HQY

Mar 18, 2025, 4:30 PM EDT - 4 months ago

Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

Mar 13, 2025, 7:00 AM EDT - 4 months ago

Tonix Pharmaceuticals Announces Presentation at BIO-Europe Spring 2025

Mar 12, 2025, 7:30 AM EDT - 4 months ago

Tonix's TNX-1500 Shows Promise in Preventing Organ Transplant Rejections of Either Human or Pig Organs; Autoimmune Diseases Also a Target

Mar 11, 2025, 7:00 AM EDT - 4 months ago

Tonix Pharmaceuticals to Present at the Zacks SCR Life Sciences Virtual Investor Forum on March 13th

Mar 10, 2025, 8:00 AM EDT - 4 months ago

Tonix Pharmaceuticals Announces Grant by Medical CBRN Defense Consortium (MCDC) for Development of TNX-801, the Company's Single-Dose Mpox and Smallpox Vaccine Candidate

Mar 5, 2025, 7:00 AM EST - 4 months ago

Tonix Pharmaceuticals to Present at the 2025 Virtual Investor Summit

Mar 4, 2025, 7:00 AM EST - 4 months ago

Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at 7th International Congress on Controversies in Fibromyalgia

Feb 7, 2025, 8:30 AM EST - 5 months ago

Tonix Pharmaceuticals Recently Announced Preliminary Full Year 2024 Operating Results and Year-End Cash

Feb 6, 2025, 8:00 AM EST - 5 months ago

Tonix Pharmaceuticals Announces Positive Topline Results from Phase 1 Trial for TNX-1500, a Next Generation anti-CD40L mAb Candidate for Prevention of Kidney Transplant Rejection and Treatment of Autoimmune Diseases

Feb 5, 2025, 7:00 AM EST - 5 months ago

Tonix Pharmaceuticals to Participate in the 2025 BIO CEO & Investor Conference

Feb 4, 2025, 7:00 AM EST - 5 months ago

Tonix Pharmaceuticals Promotes Siobhan Fogarty to Chief Technical Officer

Feb 3, 2025, 8:05 AM EST - 5 months ago

Tonix Pharmaceuticals Announces 1-for-100 Reverse Stock Split

Dec 23, 2024, 8:00 AM EST - 7 months ago

Tonix Pharmaceuticals Announces PDUFA Goal Date of August 15, 2025, for FDA Decision on U.S. Marketing Approval for TNX-102 SL for Fibromyalgia

Dec 17, 2024, 10:59 AM EST - 7 months ago

FDA accepts Tonix's NDA for non-opioid fibromyalgia drug TNX-102 SL

Dec 17, 2024, 8:00 AM EST - 7 months ago

Tonix Pharmaceuticals Announces FDA Acceptance of the New Drug Application (NDA) for TNX-102 SL for Fibromyalgia

Dec 16, 2024, 11:40 AM EST - 7 months ago

Tonix Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Highlights

Dec 9, 2024, 7:30 AM EST - 7 months ago

Tonix's TNX 102-SL Could Offer New Hope of Pain Relief Without Narcotics for Fibromyalgia Sufferers

Nov 26, 2024, 7:00 AM EST - 8 months ago

Tonix Pharmaceuticals to Participate in the NobleCon20 Investor Conference

Nov 21, 2024, 4:27 AM EST - 8 months ago

Muscarinic Acetylcholine Receptor M1 Antagonists Pipeline Research Report 2024: Comprehensive Insights on 8+ Drugs Featuring Tonix Pharmaceuticals, BMS, WinSanTor, and Apnimed

Nov 18, 2024, 4:05 PM EST - 8 months ago

Tonix Pharmaceuticals to Present at the Winter 2024 Investor Summit Virtual

Nov 14, 2024, 7:30 AM EST - 8 months ago

Tonix Pharmaceuticals Targets Rapid Migraine Relief With Non-Oral Treatments

AlwaysABullNeverABear Jul. 16 at 5:59 PM

$TNXP

0 · Reply

asweidan Jul. 16 at 5:46 PM

$TNXP The amount of selling at $44.50+ is massive. This is going to run out and then boom. However, it is massive. Many 500 shares being sold at a time.

0 · Reply

iceh9 Jul. 16 at 5:34 PM

$RGTI $TNXP

0 · Reply

BiotechBonesaw Jul. 16 at 5:20 PM

0 · Reply

Supplement Jul. 16 at 5:02 PM

2 · Reply

YEHONATAN101 Jul. 16 at 4:57 PM

$TNXP IN

0 · Reply

halokidokies Jul. 16 at 4:55 PM

$TNXP merger at rsls. Could pop more than XAGE did

0 · Reply

Joe676 Jul. 16 at 4:53 PM

$TNXP Added a few more

0 · Reply

754654DailyQualityStocks Jul. 16 at 4:50 PM

$TNXP $CRWV $BABA $BA @SRQQT

0 · Reply

Oran1 Jul. 16 at 4:49 PM

$TNXP month before approval and u sell it ? Idk what is going on

0 · Reply

StockJayC Jul. 16 at 4:43 PM

$TNXP

0 · Reply

T2HeadedEagle Jul. 16 at 4:39 PM

$TNXP what happened last time it hit $46 😬😬 I suspect the same will happen again just not as low…$15-$20 range will get touched.

1 · Reply

i8j0momma666 Jul. 16 at 4:31 PM

$TNXP .

1 · Reply

asweidan Jul. 16 at 4:27 PM

$TNXP OBV is flipping positive. $44.5-$44.70 is a block. We need to take that, so that we can start moving up to finish green today. By 2:00pm if we are in the $45-$46 range we will be in good shape. If we are in the $44-$45 range it will be a red day. Volume is not bad we should be above 700K by the EOD. We still have much selling in the $44.5-$44.7 range.

0 · Reply